203 related articles for article (PubMed ID: 28183250)
1. The Role of Target Therapy in the Treatment of Gastrointestinal Noncolorectal Cancers: Clinical Impact and Cost Consideration.
Berretta M; Romano C; Di Francia R; De Diviitis C; Canzonieri V; Caraglia M; Facchini G; Nasti G
Curr Cancer Drug Targets; 2018; 18(5):430-441. PubMed ID: 28183250
[TBL] [Abstract][Full Text] [Related]
2. Molecularly targeted therapy for advanced gastrointestinal noncolorectal cancer treatment: how to choose? Past, present, future.
Nigro O; Chini C; Proserpio I
Anticancer Drugs; 2021 Jun; 32(6):593-601. PubMed ID: 33929995
[TBL] [Abstract][Full Text] [Related]
3. Changing pathology with changing drugs: tumors of the gastrointestinal tract.
Cervera P; Fléjou JF
Pathobiology; 2011; 78(2):76-89. PubMed ID: 21677471
[TBL] [Abstract][Full Text] [Related]
4. The role of targeted therapy for gastrointestinal tumors.
Rolfo C; Bronte G; Sortino G; Papadimitriou K; Passiglia F; Fiorentino E; Marogy G; Russo A; Peeters M
Expert Rev Gastroenterol Hepatol; 2014 Nov; 8(8):875-85. PubMed ID: 24957206
[TBL] [Abstract][Full Text] [Related]
5. The Importance of Cancer Stem Cells in Gastrointestinal Cancers.
Dindar DA; Albayrak G; Ozet A
Crit Rev Oncog; 2019; 24(1):55-59. PubMed ID: 31679220
[TBL] [Abstract][Full Text] [Related]
6. Aquaporins: Their role in gastrointestinal malignancies.
Nagaraju GP; Basha R; Rajitha B; Alese OB; Alam A; Pattnaik S; El-Rayes B
Cancer Lett; 2016 Apr; 373(1):12-18. PubMed ID: 26780474
[TBL] [Abstract][Full Text] [Related]
7. Targeting dynamics of subclones of GI, liver and pancreatic cancers.
Ziogas DE; Glantzounis G; Liakakos T; Roukos DH
Expert Rev Gastroenterol Hepatol; 2016 Jul; 10(7):773-6. PubMed ID: 27143511
[No Abstract] [Full Text] [Related]
8. [MET signalling pathway and its therapeutic implications in gastrointestinal cancers].
Zaanan A; Laurent-Puig P; Taieb J
Bull Cancer; 2014 Jan; 101(1):25-30. PubMed ID: 24445683
[TBL] [Abstract][Full Text] [Related]
9. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas.
Neuzillet C; Rousseau B; Kocher H; Bourget P; Tournigand C
Pharmacol Ther; 2017 Jun; 174():145-172. PubMed ID: 28223233
[TBL] [Abstract][Full Text] [Related]
10. Clinical update on K-Ras targeted therapy in gastrointestinal cancers.
Pant S; Hubbard J; Martinelli E; Bekaii-Saab T
Crit Rev Oncol Hematol; 2018 Oct; 130():78-91. PubMed ID: 30196915
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies in gastrointestinal cancers.
Bronte G; Cicero G; Cusenza S; Galvano A; Musso E; Rizzo S; Sortino G; Roselli M; Bazan V; Fiorentino E; Russo A
Expert Opin Biol Ther; 2013 Jun; 13(6):889-900. PubMed ID: 23441760
[TBL] [Abstract][Full Text] [Related]
12. Checkpoint inhibitors in gastrointestinal cancers: Expectations and reality.
Kourie HR; Tabchi S; Ghosn M
World J Gastroenterol; 2017 May; 23(17):3017-3021. PubMed ID: 28533658
[TBL] [Abstract][Full Text] [Related]
13. Cyclooxygenase-2 in gastrointestinal malignancies.
Nagaraju GP; El-Rayes BF
Cancer; 2019 Apr; 125(8):1221-1227. PubMed ID: 30747998
[TBL] [Abstract][Full Text] [Related]
14. Targeted molecular ablation of cancer stem cells for curing gastrointestinal cancers.
Kim YS; Lee HJ; Park JM; Han YM; Kangwan N; Oh JY; Lee DY; Hahm KB
Expert Rev Gastroenterol Hepatol; 2017 Nov; 11(11):1059-1070. PubMed ID: 28707966
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors to targeted treatment in gastrointestinal carcinomas.
Silvestris N; Marech I; Brunetti AE; Azzariti A; Numico G; Cicero G; Delcuratolo S; De Luca R; Burz C; Lorusso V
Cancer Biomark; 2014; 14(2-3):151-62. PubMed ID: 24878816
[TBL] [Abstract][Full Text] [Related]
16. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 2: Neuroendocrine tumours, hepatocellular carcinoma, and gastro-intestinal stromal tumours.
Neuzillet C; de Mestier L; Rousseau B; Mir O; Hebbar M; Kocher HM; Ruszniewski P; Tournigand C
Pharmacol Ther; 2018 Jan; 181():49-75. PubMed ID: 28723416
[TBL] [Abstract][Full Text] [Related]
17. Current and future therapies for targeting HER2 mutations in gastrointestinal cancer.
El Dika I; Ilson DH
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1085-1092. PubMed ID: 30092682
[TBL] [Abstract][Full Text] [Related]
18. Targeting the PD-1 pathway: a new hope for gastrointestinal cancers.
Bilgin B; Sendur MA; Bülent Akıncı M; Şener Dede D; Yalçın B
Curr Med Res Opin; 2017 Apr; 33(4):749-759. PubMed ID: 28055269
[TBL] [Abstract][Full Text] [Related]
19. The effect of forced expression of mutated K-RAS gene on gastrointestinal cancer cell lines and the IGF-1R targeting therapy.
Matsunaga Y; Adachi Y; Sasaki Y; Koide H; Motoya M; Nosho K; Takagi H; Yamamoto H; Sasaki S; Arimura Y; Tokino T; Carbone DP; Imai K; Shinomura Y
Mol Carcinog; 2017 Feb; 56(2):515-526. PubMed ID: 27312358
[TBL] [Abstract][Full Text] [Related]
20. Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges.
Bradley CA; Salto-Tellez M; Laurent-Puig P; Bardelli A; Rolfo C; Tabernero J; Khawaja HA; Lawler M; Johnston PG; Van Schaeybroeck S;
Nat Rev Clin Oncol; 2017 Sep; 14(9):562-576. PubMed ID: 28374784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
